Incannex Healthcare

Incannex Healthcare
Incannex Healthcare
525 Collins Street, Melbourne, VIC , Australia

Incannex Healthcare Limited (IHL.ASX) is an innovator and developer of medicinal cannabinoid pharmaceutical products with global export capability.

IHL is currently undertaking 4 significant clinical programs to develop 4 uniquely formulated products in its relentless pursuit of FDA registration and market exclusivity over the following indications:

  • Obstructive Sleep Apnoea (‘OSA’)
  • Traumatic Brain Injury (‘TBI’)/Concussion
  • Sepsis Associated Acute Respiratory Distress Syndrome (‘SAARDS’)
  • Temporomandibular Joint Disorder (‘TMJD’).

Unique cannabinoid-based products targeting major unmet markets

Incannex has established first-in-class, innovative cannabinoid-based pharmaceutical therapies. Products and clinical programs have been designed to be consistent with the following ideals:

  • There is an established body of research evidence validating hypothesis for cannabinoids being efficacious in the chosen therapeutic areas
  • No current registered pharmacotherapy (drug) options are available in the patient market to compete with IHL’s four candidates
  • Strong patent opportunities and total addressable market of each therapeutic area exceeds $1 billion dollars per annum
  • Registered medications discovered may be eligible for public subsidies (e.g. PBS in Australia, Medicare, and Medicaid in the USA)
  • Accelerated commercialisation pathways remain available, including the FDA 505b(2) new drug application for product registration and market exclusivity
  • Early pre-registration sales opportunities exist under opening global medicinal cannabis access programs, including the Australian Special Access Scheme for Medicinal Cannabis.
Contact Information
Published Directory Free Tier Claimed
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x